Original Article

Hormonal Contraceptives for Endometrial Cancer Prevention in Obese and High-Risk Women in Virginia

Authors: Kyle E. Horst, MD, Susan C. Modesitt, MD

Abstract

Objectives: Endometrial cancer remains the fourth most common malignancy among US women, and hormonal contraceptives drastically reduce this risk. The study objectives were to assess the prescribing patterns, counseling practices, and knowledge of family physicians and obstetrician/gynecologists (OB/GYNs) regarding hormonal contraceptives, obesity, and cancer prevention.

Methods: A 25-question survey was mailed to 4600 OB/GYNs and family practitioners licensed in Virginia to assess self-reported hormonal contraceptive prescription practices, patient evaluation and counseling, and gynecologic oncology knowledge. χ 2 and t tests were used to assess for differences across groups. P < 0.05 was deemed significant.

Results: In total, 392 (9%) surveys were returned, with 256 (6%) being complete for analysis. The mean physician age was 53.6 years, 50.2% were men, and 92.6% of physicians prescribed hormonal contraception. Most physicians recognized decreased endometrial cancer risk associated with oral contraceptive pills (73.0%) and increased risk with obesity (95.3%), but only 36.7% consistently counseled patients on obesity-associated cancer risk. Compared with family physicians, OB/GYNs were more likely to cite endometrial cancer prevention as an indication for hormonal contraceptives (53.3% vs 10.9%, P < 0.0001); more often counseled patients on obesity-related cancer risk ( P = 0.003); and were more likely to correctly identify Lynch syndrome (69.4% vs 22.5%, P < 0.0001), diabetes mellitus (85.2% vs 38.8%, P < 0.0001), and hypertension (41.7% vs 10.1%, P < 0.0001) as risk factors for endometrial cancer. Endometrial or ovarian cancer prevention factored into <2% of total hormonal contraception prescriptions; however, OB/GYN physicians were more likely to prescribe for those indications than family physicians ( P = 0.005 and P < 0.001, respectively).

Conclusions: Family physicians and OB/GYNs could improve their knowledge of endometrial cancer risk factors and the use of hormonal contraception for chemoprevention. This represents a significant opportunity for both specialties to optimize primary endometrial cancer prevention in their increasingly obese and at-risk female patients.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Siegel R, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
 
2. American Cancer Society. Cancer facts & figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Published 2013. Accessed July 6, 2016.
 
3. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am 2012;26:1-12.
 
4. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
 
5. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
 
6. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-430.
 
7. Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012;120:998-1004.
 
8. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007;121:492-496.
 
9. Fryar CD, Carroll MD, Ogden CL. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960-1962 through 2009-2010. http://www.cdc.gov/nchs/data/hestat/obesity_adult_09_10/obesity_adult_09_10.htm. Published November 6, 2015. Accessed July 6, 2016.
 
10. Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631-650.
 
11. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’ guide to meta-analysis. Hum Reprod 1997;12:1851-1863.
 
12. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186-190.
 
13. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstst Gynaecol 2009;49:316-322.
 
14. Chan SS, Tam WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007;114:1510-1515.
 
15. Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv 2012;67:726-733.
 
16. Winfree LE, Henretta MS, Hallowell PT, et al. Pre-operative gynecologic evaluation of bariatric surgery patients: improving cancer detection in a high-risk population. J Am Coll Surg 2010;211:256-262.
 
17. Henretta MS, Copeland AR, Kelley SL, et al. Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high risk patients. Gynecol Oncol 2014;133:73-77.
 
18. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497.
 
19. Soliman PT, Bassett RL, Jr Wilson EB, et al. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol 2008;112:835-842.
 
20. Ma J, Xiao L, Stafford RS. Adult obesity and office-based quality of care in the United States. Obesity (Silver Spring) 2009;17:1077-1085.
 
21. Melamed OC, Nakar S, Vinker S. Suboptimal identification of obesity by family physicians. Am J Manag Care 2009;15:619-624.
 
22. Sussman AL, Williams RL, Leverence R, et al. The art and complexity of primary care clinicians’ preventive counseling decisions: obesity as a case study. Ann Fam Med 2006;4:327-333.
 
23. Foster GD, Wadden TA, Makris AP, et al. Primary care physicians’ attitudes about obesity and its treatment. Obes Res 2003;11:1168-1177.
 
24. Rippe JM, McInnis KJ, Melanson KJ. Physician involvement in the management of obesity as a primary medical condition. Obes Res 2001;9(Suppl 4):302S-311S.
 
25. Whitlock EP, Orleans CT, Pender N, et al. Evaluating primary care behavioral counseling interventions: an evidence-based approach. Am J Prev Med 2002;22:267-284.
 
26. US Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Am Fam Physician 2004;69:1973-1976.
 
27. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-1627.
 
28. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a “ cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105:569-754.
 
29. Ketabi Z, Mosgaard BJ, Gerdes AM, et al. Awareness of endometrial cancer risk and compliance with screening in hereditary nonpolyposis colorectal cancer. Obstet Gynecol 2012;120:1005-1012.
 
30. Hadley DW, Jenkins JF, Steinberg SM, et al. Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J Clin Oncol 2008;26:948-954.
 
31. Burton-Chase AM, Hovick SR, Sun CC, et al. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet 2014;86:185-189.
 
32. Council on Resident Education in Obstetrics and Gynecology. Educational objectives: Core curriculum in obstetrics and gynecology, 10th edition. http://www.acog.org/~/media/Departments/Members%20Only/CREOG/CREOGEducationalObjectives.pdf. Accessed May 29, 2014.
 
33. Accreditation Council for Graduate Medical Education. ACGME program requirements for graduate medical education in family medicine. http://www.acgme.org/portals/0/pfassets/programrequirements/120_family_medicine_2016.pdf. Accessed May 29, 2014.
 
34. Cummings SR, Newman TB, Hulley SB. Designing an observational study. In: Hulley SB, Cummings SR, Browner WS, et al. eds. Designing Clinical Research. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;2001:95-106.
 
35. Cummings SR, Stewart AL, Hulley SB. Designing questionnaires and data collection instruments. In: Hulley SB, Cummings SR, Browner WS, et al. eds. Designing Clinical Research. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;2001:231-246.